Source:http://linkedlifedata.com/resource/pubmed/id/10426578
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1999-9-2
|
pubmed:abstractText |
Neuropeptide Y (NPY) is a potent vasoconstrictor peptide that is abundant in the brain and the peripheral sympathetic nervous system. In the present study we investigated possible changes in plasma immunoreactive (IR)-NPY concentrations and urinary IR-NPY excretion in patients with non-insulin dependent diabetes mellitus (NIDDM) and the relationship to diabetic complications, such as nephropathy and neuropathy. IR-NPY in plasma and urine was measured by radioimmunoassay in 69 patients with NIDDM. Plasma IR-NPY concentrations in patients with advanced nephropathy (creatinine clearance <30 ml/min) (100.5 +/- 10.3 pmol/l, n=9, mean +/- SEM) were higher than in the control subjects (55.0 +/- 6.8 pmol/l, n=15) (P<0.02). Urinary excretion of IR-NPY and fractional excretion of NPY were also increased in the patients with advanced nephropathy. Sephadex G-50 column chromatography of the urine extracts obtained from healthy subjects, diabetic patients with renal failure and non-diabetic patients with renal failure showed an immunoreactive peak eluting in the NPY position. On the other hand, neither plasma nor urinary IR-NPY was high in patients with retinopathy, or in patients with peripheral neuropathy. The present study has, for the first time, shown high plasma IR-NPY concentrations and urinary IR-NPY excretion in NIDDM patients with advanced nephropathy.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0918-8959
|
pubmed:author |
pubmed-author:FukudaMM,
pubmed-author:MouriTT,
pubmed-author:MurakamiOO,
pubmed-author:NagakuboHH,
pubmed-author:OgawaSS,
pubmed-author:OhnedaMM,
pubmed-author:SatoTT,
pubmed-author:SatohCC,
pubmed-author:SatohFF,
pubmed-author:SongKK,
pubmed-author:SugimuraKK,
pubmed-author:TakahashiKK,
pubmed-author:TotsuneKK,
pubmed-author:YabeTT
|
pubmed:issnType |
Print
|
pubmed:volume |
46
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
139-46
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10426578-Adolescent,
pubmed-meshheading:10426578-Adult,
pubmed-meshheading:10426578-Aged,
pubmed-meshheading:10426578-Aged, 80 and over,
pubmed-meshheading:10426578-Blood Glucose,
pubmed-meshheading:10426578-Diabetes Mellitus, Type 2,
pubmed-meshheading:10426578-Diabetic Nephropathies,
pubmed-meshheading:10426578-Diabetic Neuropathies,
pubmed-meshheading:10426578-Diabetic Retinopathy,
pubmed-meshheading:10426578-Female,
pubmed-meshheading:10426578-Hemoglobin A, Glycosylated,
pubmed-meshheading:10426578-Humans,
pubmed-meshheading:10426578-Male,
pubmed-meshheading:10426578-Middle Aged,
pubmed-meshheading:10426578-Neuropeptide Y,
pubmed-meshheading:10426578-Reference Values
|
pubmed:year |
1999
|
pubmed:articleTitle |
Elevated plasma immunoreactive neuropeptide Y concentrations and its increased urinary excretion in patients with advanced diabetic nephropathy.
|
pubmed:affiliation |
Second Department of Internal Medicine, Tohoku University School of Medicine, Miyagi, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|